We recently found that estrogen receptor (ER) antagonists prevent highdose estrogen from inducing the formation of new cancellous bone within the medullary cavity of mouse long bones. In the present investigation, we studied the role of specific ER subtypes in this response by examining whether this is impaired in female ER␤ Ϫ/Ϫ mice previously generated by targeted gene deletion. Vehicle or 17␤-estradiol (E 2) (range 4-4,000 g ⅐ kg Ϫ1 ⅐ day Ϫ1 ) was administered to intact female ER␤ Ϫ/Ϫ mice and wild-type littermates by subcutaneous injection for 28 days. The osteogenic response was subsequently assessed by histomorphometry performed on longitudinal and cross sections of the tibia. E 2 was found to cause an equivalent increase in cancellous bone formation in ER␤ Ϫ/Ϫ mice and littermate controls, as assessed at the proximal and distal regions of the proximal tibial metaphysis. E 2 also resulted in a similar increase in endosteal mineral apposition rate in these two genotypes, as assessed at the tibial diaphysis. In contrast, cortical area in ER␤ Ϫ/Ϫ mice was found to be greater than that in wild types irrespective of E 2 treatment, as was tibial bone mineral density as measured by dual-energy X-ray absorptiometry, consistent with previous reports of increased cortical bone mass in these animals. We conclude that, although ER␤ acts as a negative modulator of cortical modeling, this isoform does not appear to contribute to high-dose estrogen's ability to induce new cancellous bone formation in mouse long bones.
istered at a relatively high dose, as assessed in studies of postmenopausal women receiving estradiol implants (9, 26) and in rodent models (2, 6) . Although higher doses of estrogen are associated with extraskeletal effects that may limit their use in postmenopausal women, improved understanding of the molecular basis for estrogen's actions on bone may provide the basis for developing novel therapeutic agents capable of targeting these.
To explore the basis for estrogen's stimulatory action on osteoblasts in more detail, we exploited previous observations that high-dose estrogen induces an exaggerated osteogenic response in mouse long bones (3, 25) . In time course studies, we found that this response consists of the generation of new cancellous bone formation surfaces, associated with a marked expansion in the bone marrow content of early osteoblast precursors (13, 15, 20) . Despite the fact that high doses of estrogen are required to induce a maximal osteogenic response in this species, we also observed that this can be inhibited by an estrogen receptor (ER) antagonist, suggesting that an ER-dependent mechanism is involved (19) . Since the recent cloning of the ␤-isoform of the ER from a rat prostate cDNA library (11) , it is now recognized that the ER exists in at least two distinct isoforms. In view of observations that ER␤ is expressed at relatively high levels in osteoblasts as assessed both in vitro and in vivo (1, 4, 5, 12, 27, 30) , it is possible that this isoform contributes to estrogen's stimulatory action on osteoblasts in mice as described above.
The generation of mice with a targeted deletion in the ER␤ gene (ER␤ Ϫ/Ϫ mice) has provided an opportunity to explore the role of ER␤ in regulating skeletal responses to estrogen. On the basis of observations that cortical bone mass is increased in female animals, ER␤ has been suggested to act as a negative modulator of cortical bone growth (31) . Although trabecular bone density in young adult female ER␤ Ϫ/Ϫ mice is unaffected (31), cancellous bone volume appears to be increased in older animals, associated with enhanced osteoblast activity (29) , suggesting that ER␤ also sup-presses osteoblast activity in cancellous bone. In the present investigation, we aimed to explore the role of ER␤ in regulating osteoblast activity in female mice by determining whether this isoform contributes to the stimulatory action of high-dose estrogen on cancellous bone formation, as assessed in long bones of female ER␤ Ϫ/Ϫ animals.
METHODS
Experimental design. ER␤ Ϫ/Ϫ mice were generated at the University of North Carolina, back-crossed onto a C57Bl/6 genetic background, transferred to the University of Bristol animal facility, and subsequently crossed with wild-type C57Bl/6 mice from the local breeding stock (10) . PCR-based genotyping was performed on DNA extracted from tail tips at 4-6 wk of age on the basis of previously published primer sets. Intact 12-wk-old female ER␤ Ϫ/Ϫ mice and age-matched wild-type littermates were subsequently administered vehicle [0.1 ml corn oil (Sigma, Poole, Dorset, UK)] or 4, 40, 400 or 4,000 g/kg 17␤-estradiol (E 2; Sigma) by daily subcutaneous injection (4-6 animals/group). This protocol was employed on the basis of our previous study (19) , where we defined the dose responsiveness of estrogen-induced osteogenesis in wild-type intact female mice.
Throughout, animals received a standard diet (Rat and Mouse Standard Diet; B&K, Humberside, UK) and water ad libitum and were kept on a 12:12-h light-dark cycle. The experimental duration was 28 days, tetracycline hydrochloride (25 mg/kg; Sigma) and calcein (30 mg/kg; Sigma) being injected intraperitoneally at 4 days and 1 day, respectively, before the mice were killed. At termination of the study, animals were killed by cervical dislocation, and long bones were removed for histomorphometric analysis. In addition, bone mineral density (BMD) was measured on whole tibiae by dual-X-ray absorptiometry with a PIXImus scanner (Lunar, Madison, WI) with small-animal software. All experimental procedures were in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Histomorphometry. All histomorphometry was performed at the proximal tibial metaphysis and tibial diaphysis. Tibiae were cleared of soft tissue, separated into proximal and distal halves, fixed in 70% ethanol for 48 h, and then dehydrated through a graded series of alcohols: 80% ethanol, 90% ethanol, and then three changes of 100% ethanol for 24 h each. Tibiae were then cleared in chloroform for 24 h, placed for a further 24 h in 100% ethanol, and embedded without decalcification in LR White Hard Grade (London Resin, Reading, UK). Longitudinal sections of the proximal portion of the tibia were then prepared for histomorphometric analysis of the proximal tibial metaphysis by use of a Reichert-Jung 2050 microtome with a "d" profile tungsten carbide knife. Sections (7 m) were stained with 1% toluidine blue in 0.01 M citrate phosphate buffer for bone area measurement, and 10-m sections were mounted unstained in Fluoromount (BDH; Laboratory Supplies, Poole, UK) for assessment by fluorescent microscopy. For analysis of the tibial diaphysis, 15-m cross sections of the distal tibial portion were obtained immediately proximal to the tibiofibular junction and prepared as above.
Histomorphometric analysis was performed using transmitted and epifluorescent microscopy linked to a computerassisted image analyzer (Osteomeasure; Osteometrics, Atlanta, GA). Two nonconsecutive sections per animal were analyzed for each parameter in a blinded manner. For the proximal tibial metaphysis, two sampling sites, each with a standard area of 0.36 mm 2 , were analyzed as previously described (20) . The proximal border of the proximal sampling site was situated 0.25 mm below the growth plate to exclude primary spongiosa (area 1); the second sampling site was immediately distal to the first sampling site (area 2). Cancellous bone area was expressed as a percentage of total tissue area [bone area (BV)/tissue area (TV)].
The length of trabecular bone perimeter covered by double label (dlS) was expressed with reference to the total tissue area (tissue area referent: dlS/TV) and as a percentage of the total length of cancellous bone perimeter (BS; cancellous perimeter referent: dlS/BS). The former parameter (i.e., dlS/ TV) was analyzed, because this gives a better reflection of estrogen's tendency to induce the appearance of new sites of cancellous bone formation than dlS/BS does (20) . Mineral apposition rate (MAR) was determined by dividing the mean distance between the tetracycline and calcein labels by the time interval between the administration of the two labels (values were not corrected for the obliquity of the plane of section).
Cortical bone parameters were assessed on cross sections of the tibial diaphysis. Cross-sectional and medullary area were analyzed on toluidine blue-stained sections, and cortical area was derived from their difference. Periosteal and endocortical dlS/BS were assesssed on unstained sections by measuring the proportion of, respectively, periosteal and endocortical surface covered by double fluorochrome label. Periosteal and endocortical MAR were derived from interlabel distance at these two surfaces.
Statistical analysis. Results are expressed as means Ϯ SE. An unpaired Student's t-test was used to examine baseline differences between wild-type and ER␤ Ϫ/Ϫ mice. Two-way analysis of variance was subsequently performed to examine whether E 2 dose or genotype exerted a statistically significant effect on the measured parameters and to study possible interactions between these two variables. The cut-off for statistical significance was taken as P ϭ 0.05.
RESULTS
Histological assessment suggested that E 2 induced the formation of new cancellous bone in the proximal tibial metaphysis to an equivalent extent in wild-type and ER␤ Ϫ/Ϫ intact female mice (Fig. 1 ). This finding was confirmed by subsequent histomorphometric analysis, which revealed that E 2 caused a similar increase in dlS/TV and BV/TV to that previously observed (19) in both ER␤ Ϫ/Ϫ mice and wild-type littermates (Fig. 2 ). These two genotypes also showed equivalent changes in dlS/TV and BV/TV at the more distal metaphysis region (Fig. 3) . Although E 2 had less tendency to stimulate MAR, our results were suggestive of a small increase at the dose of 400 g/kg to a similar extent in ER␤ Ϫ/Ϫ mice and littermate controls (Table 1 ). In contrast to the response in dlS/TV, E 2 did not increase dlS/BS, and, if anything, maximal doses E 2 tended to suppress this parameter in both ER␤ Ϫ/Ϫ and control animals.
On the basis of previous evidence that estrogen stimulates bone formation at the endocortical surface of mouse long bones, we further compared the osteogenic response of ER␤ Ϫ/Ϫ and wild-type mice by analyzing parameters of endocortical bone formation. E 2 caused a similar increase in endocortical MAR in both genotypes (Fig. 4) . In contrast, endocortical dlS/BS showed no significant response to E 2 and was reduced in ER␤ Ϫ/Ϫ mice compared with wild-type animals. E 2 caused a significant suppression in periosteal dLS/BS (Fig. 5 ), in keeping with estrogen's inhibitory action on periosteal bone growth. However, this suppression appeared to be less marked in ER␤ Ϫ/Ϫ mice, as illustrated by the significant interaction between estrogen dose and genotype.
Cortical area and cross-sectional area were both significantly increased in ER␤ Ϫ/Ϫ mice compared with littermate controls (Table 2) . Tibial BMD was also significantly higher in ER␤ Ϫ/Ϫ mice, but, unlike cortical area and cross-sectional area, this parameter additionally showed an increase after E 2 treatment (Fig. 6 ).
DISCUSSION
We compared the osteogenic response of wild-type and ER␤ Ϫ/Ϫ intact female mice with exogenous E 2 by use of the same experimental protocol as that used to define the dose-response profile of this action in wildtype animals (19) . E 2 was found to cause a similar increase in the extent of cancellous mineralizing surfaces to that previously observed in both wild-type and 
ER␤
Ϫ/Ϫ mice. Because estrogen-induced osteogenesis progresses from proximal to distal within the proximal tibial metaphysis (20) , partial suppression may be best detected by analyzing more distal regions of interest (18, 21) . However, in the present study, a similar estrogenic response was seen in the two genotypes even when the distal region was examined. Estrogeninduced osteogenesis in mouse long bones has also been reported to involve the endocortical surface (2). Consistent with this finding, we noted an increase in endocortical MAR after E 2 administration that was not significantly different between the two genotypes. These findings indicate that intact female ER␤ Ϫ/Ϫ mice show an equivalent osteogenic response to E 2 to that observed in wild-type animals.
We (19) previously found that E 2 doses, as administered in the present study, result in serum E 2 levels within the upper physiological range and beyond. Although E 2 levels were not measured in the present study, equivalent changes are likely to have occurred, in light of previous evidence that serum E 2 levels are similar in wild-type and ER␤ Ϫ/Ϫ mice (29) . Taken together, these findings suggest that ER␤ is not necessary for the osteogenic action of high estrogen levels in intact female mice. Presumably, a different ER isoform plays a major role in this response, such as ER␣. Our preliminary findings from studies of ER␣ Ϫ/Ϫ mice are consistent with this suggestion.
Our observations raise the possibility that, in addition, ER␤ is not required for the osteogenic action of Results show mean Ϯ SE mineral apposition rate (MAR) and double-labeled perimeter/bone perimeter (dlS/BS) and effects of varying doses of 17␤-estradiol (E2) on histomorphometric indexes of wild-type (WT) and estrogen receptor (ER) ␤ Ϫ/Ϫ mice as assessed at the proximal (area 1) and distal (area 2) portions of the proximal tibial metaphysis. Animals (4-7/group) were administered 0 (vehicle), 4 (E4), 40 (E40), 400 (E400), or 4,000 (E4000) g/kg E2 by daily sc injection for 28 days. Two-way ANOVA revealed a significant dose effect for dlS/BS at area 1 (P Ͻ 0.0001) and MAR at areas 1 and 2 (P Ͻ 0.05). lower levels of estrogen within the physiological range. The finding in the present study that indexes of cancellous bone formation are equivalent in untreated ER␤ Ϫ/Ϫ and wild-type animals, and previous reports that trabecular BMD is similar in these two genotypes (31) , are consistent with this possibility. Previous observations that ER␤ Ϫ/Ϫ mice are partially protected against age-related bone loss suggest that, if anything, ER␤ acts as a negative regulator with respect to effects of physiological estrogen levels on bone formation, which may reflect inhibition by ER␤ of ER␣ expression or ER␣-dependent transcription (14, 29) . However, there is no indication from the present study that the osteogenic response to high-dose E 2 is enhanced in female ER␤ Ϫ/Ϫ mice. Cross-sectional area and cortical area of the tibial diaphysis were significantly higher in ER␤ Ϫ/Ϫ mice, which is presumably the explanation for our finding that tibial BMD in these animals was also elevated. Because similar differences in diaphysial areas and tibial BMD were observed between genotypes irrespective of E 2 dose, they are likely to reflect differences in the pretreatment baseline rather than any altered responsivess to estrogen. The suggestion that cortical bone mass is increased in female ER␤ Ϫ/Ϫ mice irrespective of estrogen treatment is in line with previous phenotypic studies by Windahl et al. (31) . A likely explanation for this observation is that ER␤ contributes to estrogen's inhibitory action on bone formation at the periosteal envelope. The finding in the present study that estrogen-induced suppression of periosteal dlS/BS is reduced in ER␤ Ϫ/Ϫ female mice is consistent with this possibility.
Taken together, our observations suggest that, whereas ER␤ plays a significant role in mediating the inhibitory effects of physiological estrogen levels on cortical modeling, this isoform is not required for the osteogenic response of cancellous bone of intact female mice to high-dose estrogen. Although ER␤ is expressed by trabecular osteoblasts and stromal cells, as assessed in neonatal human and rat bone (4, 30) and adult human bone (5), presumably, these do not represent the effector cell population that mediates estrogeninduced osteogenesis in female mice. Estrogen exerts other effects, which were not examined in the present study, in cancellous bone in which ER␤ might play an important role, such as inhibition of osteoclastic bone resorption and suppression of hematopoiesis (3, 13) . After recent findings that estrogen-induced osteogenesis in female mice involves stromal cells and osteoblast precursors that express bone morphogenetic protein (BMP)-6 and the core binding transcription factor Cbfa1, respectively (15, 16) , further studies are planned to determine whether these cells preferentially co-express ER␣ or ER␤.
In view of our findings that suggest that ER␤ is not necessary for estrogen-induced osteogenesis in female mice, it is tempting to speculate that this isoform plays Results show mean Ϯ SE cross-sectional (XSA), medullary (Med), and cortical (Cort) areas in mm 2 . Animals (4-7/group) were administered 0, 4, 40, 400, or 4,000 g/kg E2 by daily sc injection for 28 days. Two-way ANOVA revealed a significant genotype effect for Cort area (P ϭ 0.03) and XSA (P ϭ 0.01). little role in estrogen's stimulatory action on osteoblasts in postmenopausal women. One implication of this conclusion is that novel ER␤-selective ligands, which have recently been developed (28), may not confer significant advantages in the treatment of postmenopausal osteoporosis compared with conventional approaches. However, any extrapolation from mice to humans should be treated with caution in view of significant species differences with respect to the skeletal actions of estrogen. For example, rather than inducing the appearance of new sites of cancellous bone formation, in humans, estrogen predominantly acts to increase mean wall thickness (9, 26) . To what extent these responses in different species are functionally related, for example due to common effects of estrogen on osteoblast precursors, is currently unclear.
In a recent study based on a different line of ER␤ Ϫ/Ϫ mice, young adult female knockout mice were found to have normal cortical bone mass but increased cancellous bone volume and reduced bone resorption (22) . These observations, which suggest that different lines of ER␤ Ϫ/Ϫ mice have distinct skeletal phenotypes, were thought to reflect initial reports that ER␤ Ϫ/Ϫ mice as used in the present study express a mutant form of ER␤ that can bind estradiol but is unable to activate gene transcription (10) . However, after reanalysis of variant ER␤ transcript sequences in ER␤ Ϫ/Ϫ mice utilized in this investigation, these were uniformly found to have stop codons (J.B. Hodgin and O. Smithies, unpublished observations), and so there is no possibility of any mutant ER␤ protein being expressed. Nevertheless, although the reasons for the apparent difference in skeletal phenotype of these two lines of ER␤ Ϫ/Ϫ mice are unclear, it may be informative to repeat our investigations with the use of ER␤ Ϫ/Ϫ mice generated by other targeting strategies.
In conclusion, we have found that estrogen-induced osteogenesis in intact female mice is unaffected by targeted gene deletion of ER␤. Therefore, although ER␤ has previously been suggested to act as a negative modulator of cortical bone modeling in mice and is reported to be highly expressed in the metaphysis, it does not appear to be necessary for the stimulatory effect of high-dose estrogen on cancellous bone formation. Further studies are required to determine whether the actions of high levels of estrogen on osteoblasts in other species such as humans are likewise independent of ER␤.
